CHAPEL HILL, N.C.–Crown Marketing (OTCQB: CWNM) is pleased to announce that Crown’s Controlled Drug Delivery Technology (CDDT) will focus on utilizing its unique and novel controlled drug delivery device to assist pharmaceutical companies in their lifecycle management strategies to extend patent life for blockbuster drugs.
With fewer products in the pipeline and blockbuster drugs edging towards the patent cliff, strategies that can extend the commercial life of mature brands are critical to bio-pharmaceutical companies today. Used properly, Lifecycle Management strategies can add several additional years of patent protection and billions of dollars of revenue for mature brands. This is critical in that these are the most profitable years of a brand’s patent life.
About The Company:
Crown Marketing’s Controlled Drug Delivery Technology (CDDT) is a novel controlled-release technology, harnessing the principles of chaos theory, precise mathematical formulas and the potentials of chemical diffusion characteristics.
The spectrum and reliability of pharmacokinetic profiles achievable with this technology is superior to currently marketed formulations. Its simple design allows for a high level of flexibility in matching chronotherapeutic requirements. Cost-efficiencies in the commercial manufacturing process, when compared to other drug delivery technologies, may constitute its most important competitive advantage.
The objective of intelligent drug delivery design amounts to maximizing the percent of the time drug plasma levels are within the therapeutic range and avoiding patient exposure to potentially toxic (High) or sub-therapeutic (Low) levels.
Crown’s cost-effective application of controlled delivery technologies will play a major role in the expansion of the pharmaceutical, OTC and nutraceuticals industry through our ability to improve on the performance of immediate release products in a manner tangible to manufacturers and consumers.
More information can be found at: www.crowncddt.com